Atezolizumab approved for use in EU as first-line treatment in metastatic non-small-cell cancer

Approval is for use in adults whose tumours have high PD-L1 expression, with no EGFR or ALK aberrations. Approval was based on the IMpower110 study which showed that atezolizumab monotherapy improved overall survival by 7.1 months in patients with high PD-L1 expression.

PharmaTimes